<DOC>
	<DOCNO>NCT02810756</DOCNO>
	<brief_summary>The pharmacokinetics new formulation Pazopanib study . This do patient cohort n = 12 .</brief_summary>
	<brief_title>Study With Improved Solubility Pazopanib</brief_title>
	<detailed_description />
	<criteria>Locally advanced metastatic cancer ; Able willing give write consent ; WHO performance status 0 , 1 2 ; Able willing undergo blood sample PK analysis ; Minimal acceptable safety laboratory value ; Negative pregnancy test female patient childbearing potential ; Able willing swallow oral medication . Any treatment investigational drug within 30 day prior receive investigational treatment ; Any treatment CYP3A4 , BCRP PGP interfere drug ; Patients receive treatment Votrient ( R ) kess 1 week ago ; Woman pregnant breast feeding ; Patients suffer know condition may influence dissolution absorption Pazopanib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>